Categories: Health

French medicine regulator bans two cannabinoid derivatives after reported side effects

Spread the love


Advertisements

France’s medicine regulator, the Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), has banned the production, sale, and use of two new families of cannabinoid derivatives because of reported serious side effects and potential addiction.

Advertisements

The ban, which took effect on 3 June, concerns both semi-synthetic (chemically modified natural) substances and synthetic products that are sold online and in shops. The semi-synthetic molecules include H4-CBD and H2-CBD, as well as certain derivatives with a chemical core called benzo[c]chromene.

Advertisements

Pure cannabidiol (CBD) and cannabinol (CBN) remain authorised, and according to an updated ANSM announcement on 4 June so do four benzo[c]chromene based products.

Advertisements
Advertisements

The synthetic products, based on …



Source link

Advertisements
Advertisements
Barbara Casassus

Share
Published by
Barbara Casassus

Recent Posts

Hurricane Beryl Highlights Dangers of Rapid Intensification. How Does This Happen? : ScienceAlert

Hurricane Beryl was the latest Atlantic storm to rapidly intensify, growing quickly from a tropical…

3 mins ago

New-look Akari taps American import Oly Okaro

Oly Okaro will be the Akari Chargers’ import for the upcoming PVL Reinforced Conference.–Photo from…

9 mins ago

The best way to enjoy and learn about the Philippines? Through food — a universal language that connects all people….

The best way to enjoy and learn about the Philippines? Through food — a universal…

22 mins ago

Bacolod mayor to address the City

Bacolod City Mayor Alfredo Abelardo Benitez will deliver his State of the City Address (Soca)…

48 mins ago

Australia politics live: Chalmers says Nationals ‘making it up as they go along’ on supermarket competition | Australian politics

Chalmers says Nationals ‘making it up as they go along’ on competition policyJim Chalmers, though,…

54 mins ago

FDA Approves Donanemab, Eli Lilly’s New Drug for Early Alzheimer’s

The Food and Drug Administration on Tuesday approved a new drug for Alzheimer’s disease, the…

1 hour ago

This website uses cookies.